A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
Neil Phippen -
Sponsor
NRG Oncology
This study is being done to answer the following question: Are there types of early-stage endometrial cancer that require less treatment than the usual approach? We are doing this study because we want to find out if this new approach is feasible and leads to a low rate of tumor returning for your early-stage endometrial cancer.
Enrollment Form
This study is currently enrolling.